Aurobindo Pharma's subsidiary CuraTeQ received Health Canada marketing authorization for Bevqolva™, its bevacizumab biosimilar.
Bevqolva™ inhibits angiogenesis to treat cancers like colorectal and lung, available in 100mg and 400mg formulations.
The product previously secured UK MHRA authorization in 2025 and is under review by European Medicines Agency.
CuraTeQ has two additional biosimilar applications currently under review by Health Canada regulators.